June 01, 2026

Troponin Testing and Early MI Discharge

Sixth-generation high-sensitivity cardiac troponin T assay classifies more patients below a low-risk threshold at presentation.

Conexiant

May 27, 2026

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Conexiant

May 27, 2026

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Conexiant

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant

May 20, 2026

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Conexiant

May 18, 2026

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Conexiant

May 14, 2026

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Conexiant

May 13, 2026

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

Conexiant

May 11, 2026

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Conexiant

May 11, 2026

Remote Diet Support Studied in Diabetes

WhatsApp-based low-carbohydrate nutrition education was linked to short-term glycemic, weight, and medication-use improvements in a small primary care trial

Conexiant